

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM716223

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
ADMA BIOLOGICS, INC.		03/23/2022	Corporation: DELAWARE
ADMA BIOMANUFACTURING, LLC		03/23/2022	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	HAYFIN SERVICES LLP		
<b>Street Address:</b>	One Eagle Place		
<b>City:</b>	London		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Postal Code:</b>	SW1Y 6AF		
<b>Entity Type:</b>	Limited Liability Partnership: UNITED KINGDOM		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5967728	ASCENIV	
<b>Registration Number:</b>	4318477	BIVIGAM	
<b>Registration Number:</b>	3015857	CIVACIR	
<b>Registration Number:</b>	2635779	NABI-HB	
<b>Registration Number:</b>	6652223	ADVANTAGE IG	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2027995000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2027994000		
<b>Email:</b>	gregory.esau@dlapiper.com		
<b>Correspondent Name:</b>	Gregory Esau		
<b>Address Line 1:</b>	500 Eighth Street, NW		
<b>Address Line 4:</b>	Washington, D.C. 20004		
<b>NAME OF SUBMITTER:</b>	Gregory Esau		
<b>SIGNATURE:</b>	/Gregory Esau/		
<b>DATE SIGNED:</b>	03/23/2022		

CH \$140.00 5967728

**Total Attachments: 8**

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page1.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page2.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page3.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page4.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page5.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page6.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page7.tif

source=Hayfin\_ADMA - Trademark Security Agreement [executed]#page8.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of March 23, 2022 (this “**Trademark Security Agreement**”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “**Trademark Grantors**”), is in favor of Hayfin Services LLP, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “**Agent**”).

W I T N E S S E T H:

WHEREAS, the Trademark Grantors are party to a Security Agreement, dated as of March 23, 2022 (as amended, supplemented or otherwise modified from time to time, the “**Security Agreement**”) in favor of the Agent, pursuant to which the Trademark Grantors are required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Trademark Grantor has created in favor of the Agent a security interest in, and the Agent has become a secured creditor with respect to, the Trademark Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Trademark Grantor hereby grants to the Agent, for the ratable benefit of the Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “**Trademark Collateral**”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Trademarks of such Trademark Grantor, including, without limitation, the registered and applied-for Trademarks of such Grantor listed on **Schedule 1** attached hereto (excluding any application for registration of a trademark filed on an intent-to-use (or equivalent) basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of such application or the resulting registration, or result in abandonment of application or cancellation of the resulting registration);

(b) to the extent not covered by **clause (a)**, all Proceeds of any of the foregoing;

(c) to the extent not covered by **clause (a)**, the goodwill of the businesses with which the Trademarks are associated; and

(d) to the extent not covered by **clause (a)**, all causes of action arising prior to or after the date hereof for infringement of any of the Trademarks or unfair competition regarding the same.

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Security Agreement, and the Trademark Grantors hereby acknowledge and affirm that the rights and remedies of the Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Trademark Grantor hereby authorizes and requests that the Commissioner of Patents and Trademarks record this Trademark Security Agreement.


**THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.**

This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Signature Pages Follow]


IN WITNESS WHEREOF, each Trademark Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first above written.

ADMA BIOLOGICS, INC.

By:   
Name: Brian Lenz  
Title: Executive Vice President, Chief Financial Officer, and Secretary

Address: ADMA Biologics, Inc.  
465 State Route 17  
Ramsey, NJ 07446

ADMA BIOMANUFACTURING, LLC

By:   
Name: Brian Lenz  
Title: Vice President, Chief Financial Officer

Address: ADMA BioManufacturing, LLC  
5800 Park of Commerce Blvd., NW  
Boca Raton, FL 33487

Accepted and Agreed:  
HAYFIN SERVICES LLP, as the Agent

By \_\_\_\_\_  
Name:  
Title Authorised Signatory

Address: One Eagle Place  
London, SW1Y 6AF  
Email: Loanops@hayfin.com  
Legal@hayfin.com  
Phone: +44 207 074 2900  
Attention: Howard Rowe  
Michael Tischler  
Legal Team / Loan Operations

[Signature Page to Trademark Security Agreement (ADMA Biologics)]

**TRADEMARK**  
**REEL: 007669 FRAME: 0219**

IN WITNESS WHEREOF, each Trademark Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first above written.

ADMA BIOLOGICS, INC.

By: \_\_\_\_\_  
Name: Brian Lenz  
Title: Executive Vice President, Chief  
Financial Officer, and Secretary

Address: ADMA Biologics, Inc.  
465 State Route 17  
Ramsey, NJ 07446

ADMA BIOMANUFACTURING, LLC

By: \_\_\_\_\_  
Name: Brian Lenz  
Title: Vice President, Chief Financial  
Officer

Address: ADMA BioManufacturing, LLC  
5800 Park of Commerce Blvd., NW  
Boca Raton, FL 33487

Accepted and Agreed:  
HAYFIN SERVICES LLP, as the Agent

By Vikas Mehta  
Name: vikas mehta  
Title Authorised Signatory

Address: One Eagle Place  
London, SW1Y 6AF  
Email: Loanops@hayfin.com  
Legal@hayfin.com  
Phone: +44 207 074 2900  
Attention: Howard Rowe  
Michael Tischler  
Legal Team / Loan Operations

Schedule 1

**TRADEMARKS**

Trademark Registrations and Applications

**Active Trademarks:**

Trademark	Country	Appl. Status	Appl./Reg. No.	Appl./Reg Date	Renewal Date	Owner	Goods
ASCENIV	IR-Australia	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Great Britain/UK	Registered	UK00801352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Egypt	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-European Union	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	International	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Israel	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Tunisia	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	U.S.A.	Registered	5,967,728	21-Jan-2020	21-Jan-2026	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
BIVIGAM	U.S.A.	Registered	4,318,477	9-Apr-2013	9-Apr-2023	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin for treatment of primary immunodeficiency disease
CIVACIR	IR-European Union	Registered	IR 887996	9-May-2006	9-May-2026	ADMA Biomanufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations
CIVACIR	IR-Great Britain/UK	Registered	UK00800887996	9-May-2006	9-May-2026	ADMA Biomanufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations
CIVACIR	International (WIPO)	Registered	IR 887996	9-May-2006	9-May-2026	ADMA Biomanufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations

CIVACIR	U.S.A.	Registered	3,015,857	15-Nov-2005	15-Nov-2025	ADMA Biomanufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations
NABI-HB	Brazil	Registered	829811818	17-Jan-2012	17-Jan-2032	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	European Union	Registered	3109048	31-Jan-2005	25-Mar-2023	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	Great Britain/UK	Registered	UK00903109	31-Jan-2005	25-Mar-2023	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	Hong Kong	Registered	301116549	15-May-2008	14-May-2028	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	International	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	IR-Ireland	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	Israel	Registered	211681	13-Apr-2010	18-May-2028	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	Taiwan	Registered	1349353	16-Feb-2009	15-Feb-2029	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	IR-Turkey	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	U.S.A.	Registered	2,635,779	15-Oct-2002	15-Oct-2022	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HB	IR-Vietnam	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
ADVANTAGE IG	U.S.A	Registered	6,652,223	22-Feb-2022	22-Feb-2032	ADMA BIOLOGICS, INC.	Cl. 36: Financial administration of medication reimbursement programs and services; providing financial consultancy services and assistance for health care; providing information on health insurance benefits and patient assistance



**Inactive Trademarks:**

<u>Trademark</u>	<u>Country</u>	<u>Status</u>	<u>Appl. No.</u>	<u>Appl. Date</u>	<u>Owner</u>	<u>Goods</u>
ADVIGA	IR-Australia	Not Active	IR 1352669	10-May-2017	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-Egypt	Not Active	IR 1352669	10-May-2017	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-European Union	Not Active	IR 1352669	10-May-2017	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	International (WIPO)	Not Active	IR 1352669	10-May-2017	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-Israel	Not Active	IR 1352669	10-May-2017	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-Tunisia	Not Active	IR 1352669	10-May-2017	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	U.S.A.	Not Active	87/012,343	25-APR-2016	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
BIVIGAM CARES	U.S.A.	Not Active	4,430,011	05-Nov-2013	ADMA Biologics	Cl. 36: Insurance services, namely, insurance administration services to assist patients
FOR UNCOMPROMISED LIVING	U.S.A.	Not Active	4,495,929	11-Mar-2014	ADMA BioManufacturing, LLC	Cl. 16: Brochures about primary Immunodeficiency medicine
GAMIVRA	IR-Australia	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - Egypt	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - European Union	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	International (WIPO)	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - Israel	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - Tunisia	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	U.S.A.	Not Active	86/520,117	23-Jun-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
INSPIRED	U.S.A.	Not Active	4,404,516	17-Sep-2013	ADMA Biologics	Cl. 16: Publications, namely, patient support booklets, pamphlets, patient guides, support

SUPPORT FOR THE PI COMMUNITY						newsletters, brochures, and bulletins in the fields of primary immunodeficiency (PI) medicine and support for patients with that diagnosis  Cl. 44: Providing a web site featuring medical information; providing an internet website for medical professionals and medical patients
NABI-HB	Canada	Not Active	1043185	17-Feb-2004	Nabi Pharmaceuticals	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
NABI-HB	Egypt	Not Active	220944	29-Nov-2010	Nabi Pharmaceuticals	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
NABI-HB	India	Not Active	1688433	13-May-2008	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparation for the prevention or treatment of hepatitis
RESPIMMUNE	U.S.A.	Not Active	86/414,489	03-Oct-2014	ADMA Biologics	Cl. 5: Pharmaceutical preparations, namely, immune globulins
RESYNRUS	IR - Australia	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Egypt	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Europe	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	Internaitonal (WIPO)	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR – Israel	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Tunisia	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	U.S.A.	Not Active	86/520,133	23-Jun-2015	ADMA Biologics	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders